AstraZeneca Combo for Type 2 Diabetes Gets Green Light in EU

The EMA has given the green light to a fixed-dose combination of saxagliptin and dapagliflozin, the first combination of DPP-4/SGLT2 inhibitor in Europe, for the treatment of type 2 diabetes.